Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily CSI China Internet Bull 2X Shares vs Cassava Sciences Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $22.96, while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Direxion Daily CSI China Internet Bull 2X Shares is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| CWEB | FLNA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $60.13 | $4.64 |
52-Week Low | $17.70 | $1.09 |
Market Cap | — | $52.66M |
Enterprise Value | — | -$33.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $21.61, down 1.46% today, with technical indicators showing a bullish bias from moving averages but a neutral stance from oscillators. The stock lacks recent fundamental data, with key valuation and profitability ratios unavailable. A dividend of $0.09 is scheduled for June 2026, indicating a potential income component.
The outlook is mixed due to incomplete financials; technical strength offers near-term upside potential, but investment decisions require updated earnings and revenue figures. Risks include data gaps and market volatility, warranting caution until fundamental clarity emerges from SEC filings or company announcements.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
